Annual Report and Form 20-F Information

The report describes AstraZeneca's strong 2022 growth, including Total Revenue of $44,351 million, while presenting sustainability as a Board-approved strategic priority. It highlights progress under Ambition Zero Carbon, including verified net-zero targets across Scopes 1, 2 and 3 and targets for major emissions reductions through 2045. The report also provides detailed 2022 GHG and energy data, including Scope 3 emissions across all 15 categories, and discloses limited external assurance by Bureau Veritas over specified sustainability information.